Ready to model the future a:head is a biotech company that follows a unique approach to drug development by leveraging the groundbreaking brain organoid technology to develop new therapeutics for neurological disorders. We are located at the Vienna BioCenter (VBC), a vibrant cluster of universities, research institutes, and biotech companies in Austria. We are searching for a highly [...]
Ready to model the future a:head is a biotech company that follows a unique approach to drug development by leveraging the groundbreaking brain organoid technology to develop new therapeutics for neurological disorders. We are located at the Vienna BioCenter (VBC), the vibrant cluster of universities, research institutes, and biotech companies in Austria. We are searching for a highly [...]
Ready to model the future a:head is a biotech company that follows a unique approach to drug development by leveraging the groundbreaking brain organoid technology to develop new therapeutics for neurological disorders. We are located at the Vienna BioCenter (VBC), the vibrant cluster of universities, research institutes, and biotech companies in Austria. We are searching [...]
After securing more than EUR 4 million of private and public funding in 2019, a:head today closed another 7-digit EUR equity round with a consortium of investors including red stars.com data AG, the company’s seed investor.
a:head bio AG today announced a long-term partnership with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria for the development of next generation central nervous system (CNS) therapeutics and the award of an Early Stage grant from the Austrian Research Promotion Agency (FFG)